Table 2.
Risks of Primary and Secondary Malignancy Endpoints by Treatment Arm
| Simvastatin Monotherapy (n = 8,855) |
Simvastatin/Ezetimibe (n = 8,853) |
|||||
|---|---|---|---|---|---|---|
| n | Kaplan-Meier Event Rate at 7 Years (%) | n | Kaplan-Meier Event Rate at 7 Years (%) | HR (95% CI) | p Value | |
| Primary endpoint | ||||||
| New, relapsing, or progressive malignancy (excluding nonmelanotic skin malignancy) | 726 | 10.3 | 744 | 10.2 | 1.03 (0.93–1.14) | 0.56 |
| Secondary endpoints | ||||||
| New, relapsing, or progressive malignancy (including nonmelanotic skin malignancy) | 908 | 12.8 | 905 | 12.5 | 1.00 (0.91–1.10) | 0.99 |
| New malignancy (excluding nonmelanotic skin, relapsing, or progressive malignancies) | 674 | 9.7 | 690 | 9.6 | 1.03 (0.92–1.14) | 0.63 |
| New malignancy (including nonmelanotic skin malignancy and excluding relapsing or progressive malignancy) | 857 | 12.2 | 851 | 11.9 | 0.99 (0.90–1.09) | 0.90 |
| New, relapsing, or progressive malignancy (excluding nonmelanotic skin malignancy) | 629 | 8.9 | 640 | 8.8 | 1.02 (0.92–1.14) | 0.67 |
| Deaths due to malignancy | 268 | 3.6 | 277 | 3.8 | 1.04 (0.88–1.23) | 0.68 |
CI = confidence interval; HR = hazard ratio.